The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance
Open accessAbstract
Small intestinal bacterial overgrowth (SIBO) is defined as the presence of an abnormally high number of coliform bacteria in the small bowel. It is associated with a broad range of predisposing small intestinal motility disorders and with surgical procedures that result in bowel stasis. The most common symptoms associated with SIBO include diarrhea, flatulence, abdominal pain and bloating. Quantitative culture of small bowel contents and a variety of indirect tests have been used over the years in an attempt to facilitate the diagnosis of SIBO. The indirect tests include breath tests and biochemical tests based on bacterial metabolism of a variety of substrates. Unfortunately, there is no single valid test for SIBO, and the accuracy of all current tests remains limited due to the failure of culture to be a gold standard and the lack of standardization of the normal bowel flora in the small intestine. Currently, the ideal approach to treat SIBO is to treat the underlying disease, eradicate overgrowth, and address nutritional deficiencies that may be associated with the development of SIBO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Self-citationSmall intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 1×
“The bacteria typically recognized as SIBO are mainly of the colonic type and are thus predominantly gramnegative aerobes and anaerobic species that ferment carbohydrates into gas [Posserud et al. 2007; Sachdev and Pimental, 2012].”
BackgroundSmall Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396
A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth
Khoshini, R., Dai, S.-C., Lezcano, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0065-1 · Cited by 323
Self-citationBouhnik, Y., Alain, S., Attar, A., Flourié, B., Raskine, L., Sanson-Le Pors, M. J., & Rambaud, J.-C. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01016.x · Cited by 199
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
Koo, H. L., & DuPont, H. L. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328333dc8d · Cited by 189 · cited 1×
“Rifaximin has gained popularity since it is nonabsorbed, has few side effects and little evidence for resistance [Frissora and Cash, 2007; Koo and Dupont, 2010].”
BackgroundSmall‐intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease
PANDE, C., KUMAR, A., & SARIN, S. K. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03994.x · Cited by 152
Compare, D., Pica, L., Rocco, A., De Giorgi, F., Cuomo, R., Sarnelli, G., Romano, M., & Nardone, G. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02419.x · Cited by 122
Research works printed but not linked: 48
- 10.1016/S0016-5085(99)70336-7 · DOI · Paper page
- 10.1016/S0140-6736(87)91231-1 · doi:10.1016/s0140-6736(87)91231-1
- 10.1172/JCI106916 · DOI · Paper page
- 10.1006/mpat.1996.0122 · DOI
- 10.1007/s11894-007-0059-3 · DOI
- 10.1016/j.numecd.2012.02.007 · DOI · Paper page
- 10.1046/j.1365-2036.2000.00808.x · DOI
- 10.1023/A:1010722314493 · DOI
- 10.1111/j.1365-2036.2009.03970.x · DOI
- 10.1073/pnas.0706625104 · DOI · Paper page
- 10.1111/j.1365-2036.2007.03313.x · DOI
- 10.1345/aph.1K345 · DOI
- 10.1007/BF02236706 · DOI
- 10.1159/000103892 · DOI · Paper page
- 10.1186/1471-230X-4-10 · DOI
- 10.1186/1471-230X-3-9 · DOI
- 10.1093/ajcn/29.7.754 · doi:10.1093/ajcn/29.7.754
- 10.1556/OH.2012.29419 · DOI
- 10.1016/0016-5085(88)90173-4 · DOI · Paper page
- 10.1016/0016-5085(86)90199-X · DOI
- 10.1016/j.giec.2006.03.005 · DOI
- 10.1016/0016-5085(83)90005-7 · DOI
- 10.1111/j.1572-0241.2008.02030.x · DOI · Paper page
- 10.1016/j.cgh.2009.12.022 · DOI · Paper page
- 10.1111/j.1365-2036.2005.02690.x · DOI · Paper page
- 10.1016/S1665-2681(19)31457-7 · DOI
- 10.1155/2011/604643 · DOI
- 10.1016/j.cgh.2008.02.054 · DOI · Paper page
- 10.1111/j.1572-0241.2007.01758.x · DOI
- 10.1007/s11938-007-0076-1 · DOI
- 10.1007/s10620-011-1728-5 · DOI · Paper page
- 10.7326/0003-4819-145-8-200610170-00004 · DOI · Paper page
- 10.1016/j.idc.2010.07.007 · DOI
- 10.1055/s-0029-1245705 · DOI
- Riordan S., 1995, Am J Gastroenterol, 90, 1455
- Riordan S., 1996, Am J Gastroenterol, 91, 1795
- 10.1097/MCG.0b013e3181557e67 · DOI
- 10.1007/s11695-007-9398-2 · DOI · Paper page
- 10.1007/s11894-012-0284-2 · DOI
- 10.1146/annurev.mi.31.100177.000543 · DOI · Paper page
- 10.1007/s11938-004-0022-4 · DOI
- 10.1159/000007753 · DOI
- 10.1016/S0022-3476(05)81033-9 · DOI
- Toskes P., 1993, Adv Intern Med, 38, 387
- 10.1185/03007999909115173 · DOI
- 10.1097/00005176-199808000-00005 · doi:10.1097/00005176-199808000-00005 · Paper page
- 10.1016/j.sleep.2011.03.007 · DOI
- 10.1007/s10620-007-9839-8 · DOI · Paper page
Cited by
The progress of gut microbiome research related to brain disorders
Zhu, S., Jiang, Y., Xu, K., Cui, M., Ye, W., Zhao, G., Jin, L., & Chen, X. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1705-z · Cited by 419
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.005 · Cited by 266
Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders
Singh, R., Zogg, H., Wei, L., Bartlett, A., Ghoshal, U. C., Rajender, S., & Ro, S. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20149 · Cited by 259
Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms
Felice, V. D., Quigley, E. M., Sullivan, A. M., O'Keeffe, G. W., & O'Mahony, S. M. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.03.012 · Cited by 205
Metadata
- Authors
- Sachdev, A. H., & Pimentel, M.
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2013-07-16
- Volume
- 4
- Issue
- 5
- Pages
- 223-231
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- OpenAlex
- W2069636981
- Cited by
- 187
- References
- 10
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. https://app.cochat.ai/papers/10.1177/2040622313496126
- The paper
- Sachdev, A. H., & Pimentel, M. (2013). Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622313496126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.